in water, precipitated in the presence of polyethylene glycol; glycerol was thus used instead. 246
An additional benefit of using glycols is their role in reducing the evaporation of the solvent, 247 as they act as humectants (Raijada et al., 2014) . Rapid evaporation of the solvent can lead 248 to the clogging of the nozzle due to the precipitation of the components of the formulation at 249 the nozzle's tip. Polyethylene glycol, however, has been reported to have central nervous 250 system-related adverse side effects in children in large doses (Walsh et al., 2011) . 
Substrates 285
Substrates are an administrable carrier on which the drug solution is printed. For oral 286 administration it is important that the substrate can be ingested. While the ability to jet many 287 drugs has been demonstrated, some studies do not deposit the active onto substrates fit for 288 human consumption. it back into a printer multiple times. A clear deviation from the predicted dose was seen and 325 it was argued that this was due to the contact of the substrate with the rollers of the printer. 
Conclusions 537
Ink-jet printing is capable of printing solutions and/or nanosuspensions onto a wide range of 538 solid substrates, making it a suitable technology for the manufacture of a wide range for oral 539 dosage forms. When considering the use of ink-jet printing for pharmaceutical manufacture, 540 preformulation studies will be required to ensure solutions have suitable properties for 541 jetting; control of viscosity and surface tension are paramount, plus it is important to ensure 542 that the API doesn't precipitate from solution in the printer. Once a solution is optimised for 543 printing consideration must be given to the physical form of the drug in the dosage form. 544
When the basic formulation has been developed, there is the potential to use the technology 545 to fabricate personalised doses and/or drug combinations. 546 the physicochemical properties of the solution to match the requirements of the printer. For 550 production of medicines for human use the printer technology can be optimised for a 551 particular solution. Widespread adoption of ink-jet printing for pharmaceutical manufacture 552 will require consideration of GMP. 553 554 Ink-jet printing will not replace traditional methods of manufacturing medicines, at least in the 555 short term, and it is unlikely to be used for large-scale mass production. The small volumes 556 the printer can dispense combined with the low concentrations needed to prevent clogging 557 means the technology is more suited to printing drugs with low therapeutic doses. 558
Knowledge of whether ink-jet technology could be expanded to print high dose drugs is 559 unknown. In the meantime, for low dose drugs with narrow therapeutic windows, ink-jetting 560
printing can produce precise, accurate and reproducible doses and offers the potential of 561 fabricating doses specific to the patient. 
